Mirko Marabese

Istituto di Ricerche Farmacologiche Mario Negri

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (8)

Year:

2025

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Angela Rizzo

University of Milan

ITALY

View details

Adele Busico

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

MASSIMO BROGGINI

Laboratory Head

Istituto di Ricerche Farmacologiche Mario Negri

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mirko Marabese

Research Interests

Explore related searches

Contact this professor

Articles (8)

Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)

LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.

Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation

Predicting the Role of DNA Polymerase β Alone or with <i>KRAS</i> Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.

LKB1ness Dictates ERK Inhibitors Response in NSCLC.

Collaborators (3)

Angela Rizzo

Adele Busico

MASSIMO BROGGINI

Make your next move.